People · Operator
Named in public records as an officer, director or promoter · active 2017–2017 · Pharmaceuticals
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Amplyx Pharmaceuticals, Inc. | — | Pharmaceuticals | Series C | $116.6M | $3.2B | 2017 |
Johan K?rdel at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Johan K?rdel on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Edward Mathers | 1 | 12 |
| Ed Mathers | 1 | 11 |
| Michael Grey | 1 | 10 |
| ANAND MEHRA | 1 | 7 |
| Paul Grint | 1 | 5 |
| Alan Fuhrman | 1 | 5 |
| Mitchell Mutz | 1 | 5 |
| Johan Kordel | 1 | 4 |
| Elaine Heron | 1 | 3 |
| Karen Talmadge | 1 | 3 |
| Chrysa Mineo | 1 | 2 |
| Ciara Kennedy | 1 | 2 |
| Santosh Vetticaden | 1 | 2 |
| Mike Hodges | 1 | 1 |
| Jack Florio | 1 | 1 |
| Niall ODonnell | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.